 Blair Fennimore
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 5 | 2022 | 289 | 1.050 |
Why?
| | Colon | 3 | 2020 | 234 | 0.780 |
Why?
| | Colitis | 2 | 2020 | 226 | 0.750 |
Why?
| | Mucoproteins | 1 | 2020 | 10 | 0.740 |
Why?
| | Cholestasis | 2 | 2020 | 225 | 0.720 |
Why?
| | Cholangitis, Sclerosing | 1 | 2020 | 74 | 0.680 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 168 | 0.680 |
Why?
| | Bile Acids and Salts | 1 | 2020 | 172 | 0.670 |
Why?
| | Gastrointestinal Diseases | 2 | 2015 | 184 | 0.540 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2015 | 7 | 0.520 |
Why?
| | Nausea | 1 | 2015 | 103 | 0.500 |
Why?
| | Myositis | 1 | 2015 | 44 | 0.500 |
Why?
| | Muscle, Smooth | 1 | 2015 | 150 | 0.480 |
Why?
| | Abdominal Pain | 1 | 2015 | 135 | 0.470 |
Why?
| | Gastrointestinal Microbiome | 4 | 2022 | 503 | 0.460 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 43 | 0.360 |
Why?
| | Spondylarthritis | 2 | 2021 | 36 | 0.330 |
Why?
| | Crohn Disease | 2 | 2021 | 197 | 0.300 |
Why?
| | Intestines | 2 | 2021 | 324 | 0.290 |
Why?
| | Intestinal Mucosa | 3 | 2019 | 528 | 0.260 |
Why?
| | Disease Susceptibility | 2 | 2021 | 316 | 0.200 |
Why?
| | Ursodeoxycholic Acid | 1 | 2020 | 21 | 0.180 |
Why?
| | Ustekinumab | 1 | 2020 | 12 | 0.180 |
Why?
| | Dextran Sulfate | 1 | 2020 | 70 | 0.180 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 7 | 0.180 |
Why?
| | Tryptophan | 1 | 2021 | 136 | 0.170 |
Why?
| | Metagenomics | 1 | 2021 | 131 | 0.170 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 60 | 0.170 |
Why?
| | Antiporters | 1 | 2019 | 18 | 0.170 |
Why?
| | Metabolomics | 2 | 2022 | 538 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 667 | 0.160 |
Why?
| | Colitis, Ulcerative | 1 | 2020 | 105 | 0.160 |
Why?
| | Acidosis | 1 | 2019 | 87 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2020 | 1137 | 0.160 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 12 | 0.160 |
Why?
| | Aldehydes | 1 | 2019 | 144 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2020 | 138 | 0.140 |
Why?
| | Mice, Knockout | 2 | 2020 | 2604 | 0.140 |
Why?
| | Liver Diseases | 1 | 2019 | 263 | 0.140 |
Why?
| | Biopsy | 2 | 2020 | 1056 | 0.130 |
Why?
| | Adenosine | 2 | 2019 | 203 | 0.130 |
Why?
| | Antioxidants | 1 | 2019 | 533 | 0.130 |
Why?
| | CD3 Complex | 1 | 2015 | 92 | 0.130 |
Why?
| | Reproduction | 1 | 2016 | 180 | 0.120 |
Why?
| | Mothers | 1 | 2021 | 666 | 0.120 |
Why?
| | Microbiota | 1 | 2022 | 652 | 0.120 |
Why?
| | Intestine, Small | 1 | 2015 | 125 | 0.120 |
Why?
| | Neutrophils | 1 | 2019 | 1172 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3580 | 0.120 |
Why?
| | Inflammation | 3 | 2019 | 2499 | 0.120 |
Why?
| | Lymphocytes | 1 | 2015 | 344 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2019 | 1093 | 0.110 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2013 | 68 | 0.110 |
Why?
| | Radiography | 1 | 2015 | 826 | 0.110 |
Why?
| | A Kinase Anchor Proteins | 1 | 2013 | 65 | 0.110 |
Why?
| | Humans | 18 | 2022 | 115587 | 0.100 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2013 | 249 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2016 | 430 | 0.100 |
Why?
| | Liver | 1 | 2019 | 1690 | 0.100 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1357 | 0.100 |
Why?
| | Cost-Benefit Analysis | 3 | 2020 | 548 | 0.090 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 447 | 0.090 |
Why?
| | Mice | 4 | 2020 | 15052 | 0.090 |
Why?
| | Adenoma | 1 | 2012 | 187 | 0.090 |
Why?
| | Colonoscopy | 1 | 2012 | 204 | 0.090 |
Why?
| | Infliximab | 2 | 2020 | 94 | 0.090 |
Why?
| | Platelet Membrane Glycoproteins | 1 | 2009 | 37 | 0.090 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 553 | 0.090 |
Why?
| | Gram-Positive Bacteria | 1 | 2009 | 46 | 0.090 |
Why?
| | Early Detection of Cancer | 1 | 2012 | 340 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 192 | 0.080 |
Why?
| | Animals | 5 | 2020 | 32102 | 0.070 |
Why?
| | Up-Regulation | 2 | 2019 | 820 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2012 | 617 | 0.070 |
Why?
| | HIV Infections | 1 | 2020 | 2473 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2012 | 1180 | 0.060 |
Why?
| | Female | 7 | 2021 | 59913 | 0.060 |
Why?
| | Algorithms | 2 | 2020 | 1490 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3022 | 0.050 |
Why?
| | Adult | 5 | 2020 | 30718 | 0.050 |
Why?
| | Granzymes | 1 | 2021 | 40 | 0.050 |
Why?
| | Adalimumab | 1 | 2020 | 44 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 50 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 22 | 0.040 |
Why?
| | Models, Economic | 1 | 2020 | 48 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2019 | 21 | 0.040 |
Why?
| | Leukocyte Disorders | 1 | 2019 | 11 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 103 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 114 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 168 | 0.040 |
Why?
| | Lactation | 1 | 2021 | 149 | 0.040 |
Why?
| | Receptors, CCR5 | 1 | 2020 | 54 | 0.040 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2019 | 29 | 0.040 |
Why?
| | Feces | 1 | 2022 | 372 | 0.040 |
Why?
| | Immune System Diseases | 1 | 2019 | 35 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 87 | 0.040 |
Why?
| | Milk, Human | 1 | 2021 | 128 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 146 | 0.040 |
Why?
| | Neutrophil Activation | 1 | 2019 | 94 | 0.040 |
Why?
| | Glutathione Transferase | 1 | 2019 | 95 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 125 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 284 | 0.040 |
Why?
| | Ribosomes | 1 | 2019 | 148 | 0.040 |
Why?
| | Middle Aged | 4 | 2020 | 26999 | 0.040 |
Why?
| | Antigens, CD | 1 | 2020 | 442 | 0.040 |
Why?
| | Biological Products | 1 | 2020 | 172 | 0.040 |
Why?
| | Aged | 1 | 2015 | 19251 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1377 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 962 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2019 | 332 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 536 | 0.040 |
Why?
| | Male | 5 | 2020 | 55949 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 682 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 924 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 666 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 476 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1598 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2020 | 440 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 639 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1536 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1756 | 0.030 |
Why?
| | Proteomics | 1 | 2019 | 859 | 0.030 |
Why?
| | Hospitalization | 1 | 2022 | 1765 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2013 | 220 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 346 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2019 | 3914 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 4773 | 0.020 |
Why?
| | Caco-2 Cells | 1 | 2009 | 66 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6264 | 0.020 |
Why?
| | Health Care Costs | 1 | 2012 | 384 | 0.020 |
Why?
| | Isoenzymes | 1 | 2009 | 285 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 302 | 0.020 |
Why?
| | Biological Transport | 1 | 2009 | 375 | 0.020 |
Why?
| | RNA Interference | 1 | 2009 | 438 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2009 | 340 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 2651 | 0.020 |
Why?
| | Infant | 1 | 2021 | 7979 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 8697 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4541 | 0.020 |
Why?
| | Cell Membrane | 1 | 2009 | 683 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 12608 | 0.020 |
Why?
| | Pregnancy | 1 | 2016 | 5548 | 0.020 |
Why?
| | Young Adult | 1 | 2020 | 10470 | 0.020 |
Why?
| | Hypoxia | 1 | 2009 | 937 | 0.010 |
Why?
| | Child | 1 | 2022 | 18488 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 17889 | 0.010 |
Why?
|
|
Fennimore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|